NeurologyLive® Friday 5 — October 24, 2025

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: MDS Congress 2025: Top Expert Interviews and Key Takeaways

Experts shared their clinical perspectives on trending topics in the treatment and management of movement disorders at the 2025 International Congress of Parkinson’s Disease and Movement Disorders (MDS).

2: Refining Neonatal Continuous EEG Guidelines Through Evidence and Family Collaboration: Adam Numis, MD

The associate professor of neurology and pediatrics at the University of California, San Francisco, discussed updated recommendations for continuous EEG use in neonates, highlighting risk stratification, and the growing importance of family involvement. [WATCH TIME: 3 minutes]

3: Testing D1 Receptor Modulator Glovadalen in Phase 2 Trial for Parkinson Disease: Milton Biagioni MD, CMD

At MDS 2025, the senior medical director of UCB's Translational Medicine Neuroscience and Gene Therapy presented data from the ATLANTIS study of glovadalen in patients with Parkinson disease. [WATCH TIME: 4 minutes]

4: NeuroVoices: Gerald Maguire, MD, on Raising Awareness of the Neurobiology of Stuttering

In honor of International Stuttering Awareness Day, the founder of the Stuttering Treatment and Research Society (STARS) discussed understanding the diagnosis of stuttering and the importance of early intervention for patients.

5: Understanding Key Clinical and Genetic Biomarkers in Huntington Disease Research: Sarah O'Shea, MD, MSc

The associate professor of neurology at the Icahn School of Medicine at Mount Sinai talked about the major biomarkers used to track progression in Huntington disease. [WATCH TIME: 5 minutes]